Apimeds Pharmaceuticals US, Inc. Stock Price

NYSEAM:APUS Community·US$25.7m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

APUS Share Price Performance

US$2.19

-0.01 (-0.45%)

US$2.19

-0.01 (-0.45%)

US$2.19

Sat, 1 Nov 25

Share PriceUS$2.19

APUS Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Excellent balance sheet with slight risk.

4 Risks

0 Rewards

View Full Analysis

Apimeds Pharmaceuticals US, Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.29
: 0%
: 0%
: 5.1%

View Full Analysis

About APUS

Founded: 2020
Employees: 2
CEO: Erik Emerson
WebsiteView website: www.apimedsus.com

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, a purified, pharmaceutical grade venom of the Apis mellifera, or honeybee for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company has a strategic alliance with University of Alabama for the development of ai² future labs program. The company was incorporated in 2020 and is based in Matawan, New Jersey.